Loading
Life sciences · Journal article
Cancer Biotherapy and Radiopharmaceuticals · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: Particularly for patients with bone-dominant illness, targeted radionuclide treatments are becoming a viable treatment option for metastatic prostate cancer (PCa). Precision treatment selection and improved therapeutic outcomes may result from early detection of patients who are at high risk of developing bone metastases. To identify early-stage PCa patients at increased risk of postoperative bone metastasis who might benefit from targeted radionuclide therapy, this study sought to develop and validate a multimodal predictive model that integrated biparametric magnetic resonance imaging (bpMRI) radiomics features and serum bone turnover biomarkers. Methods: A total of 143 patients with clinically localized PCa (cT1–2N0M0) receiving laparoscopic radical prostatectomy were included in this prospective single-center cohort analysis. Bone metabolism indicators, such as osteocalcin N-terminal mid-fragment and alkaline phosphatase, were measured in serum prior to surgery. bpMRI was used to extract radiomics variables that reflected the tumor microenvironment and perfusion characteristics (apparent diffusion coefficient mean and K trans mean). Serum and imaging biomarkers were integrated using a multivariate logistic regression model. Receiver operating characteristic (ROC) analysis, calibration curves, decision curve analysis, and Kaplan–Meier survival analysis for bone metastasis-free survival were used to assess the model’s performance. Results: With an area under the ROC curve of 0.984, the integrated multimodal model outperformed individual biomarkers and imaging features by a significant margin (all p < 0.001). In decision curve analysis, the model demonstrated significant clinical net benefit and strong calibration (Hosmer–Lemeshow test p = 0.830). Patients were categorized into high-risk ( n = 53) and low-risk ( n = 90) groups according to risk stratification based on the model, with significantly different bone metastasis–free survival results (log-rank p < 0.001). Conclusions: A reliable method for anticipating postoperative bone metastases in early-stage PCa is a multimodal framework that combines bpMRI radiomics with blood bone turnover indicators. This strategy may facilitate early treatment intervention in individuals with increased metastatic risk and support precision patient selection for targeted radionuclide therapy.